Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageEnterprise ValueEquity AverageEquity RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on Equity

Benitec Biopharma (BNTC) Gross Margin (2019 - 2023)

Benitec Biopharma's Gross Margin history spans 5 years, with the latest figure at 100.0% for Q2 2023.

  • For Q2 2023, Gross Margin changed N/A year-over-year to 100.0%; the TTM value through Mar 2024 reached 1471.43%, down 155819.0%, while the annual FY2023 figure was 100.0%, 1233.0% up from the prior year.
  • Gross Margin for Q2 2023 was 100.0% at Benitec Biopharma, roughly flat from 100.0% in the prior quarter.
  • Across five years, Gross Margin topped out at 1950.0% in Q2 2021 and bottomed at 1800.0% in Q4 2020.
  • The 5-year median for Gross Margin is 100.0% (2021), against an average of 5.13%.
  • The largest annual shift saw Gross Margin tumbled -150260bps in 2020 before it surged 196707bps in 2021.
  • A 5-year view of Gross Margin shows it stood at 297.4% in 2019, then crashed by -505bps to 1800.0% in 2020, then soared by 106bps to 100.0% in 2021, then changed by 0bps to 100.0% in 2022, then changed by 0bps to 100.0% in 2023.
  • Per Business Quant, the three most recent readings for BNTC's Gross Margin are 100.0% (Q2 2023), 100.0% (Q1 2023), and 100.0% (Q4 2022).